Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TECH 
Bio-Techne Corp (TECH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: TECH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $75.25
1 Year Target Price $75.25
| 7 | Strong Buy |
| 3 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.06B USD | Price to earnings Ratio 109.28 | 1Y Target Price 75.25 |
Price to earnings Ratio 109.28 | 1Y Target Price 75.25 | ||
Volume (30-day avg) 15 | Beta 1.47 | 52 Weeks Range 45.74 - 72.06 | Updated Date 02/27/2026 |
52 Weeks Range 45.74 - 72.06 | Updated Date 02/27/2026 | ||
Dividends yield (FY) 0.55% | Basic EPS (TTM) 0.53 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-02-04 | When - | Estimate 0.43 | Actual 0.46 |
Profitability
Profit Margin 6.67% | Operating Margin (TTM) 19.67% |
Management Effectiveness
Return on Assets (TTM) 6.52% | Return on Equity (TTM) 3.97% |
Valuation
Trailing PE 109.28 | Forward PE 30.4 | Enterprise Value 9948877751 | Price to Sales(TTM) 7.45 |
Enterprise Value 9948877751 | Price to Sales(TTM) 7.45 | ||
Enterprise Value to Revenue 8.16 | Enterprise Value to EBITDA 45.87 | Shares Outstanding 156453292 | Shares Floating 154585240 |
Shares Outstanding 156453292 | Shares Floating 154585240 | ||
Percent Insiders 0.68 | Percent Institutions 114 |
Upturn AI SWOT
Bio-Techne Corp
Company Overview
History and Background
Bio-Techne Corp. (formerly R&D Systems) was founded in 1976. It has evolved into a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Key milestones include its rebranding to Bio-Techne in 2014 and several strategic acquisitions to expand its product portfolio and market reach.
Core Business Areas
- Protein Sciences: Designs, manufactures, and sells a broad range of high-quality purified proteins, antibodies, immunoassays (ELISAs), and related reagents for research and diagnostic applications. This segment is the historical core of the company.
- Clinical Diagnostics and Advanced Diagnostics: Offers a portfolio of diagnostic products and platforms, including molecular diagnostics, flow cytometry reagents, and assays for disease detection and monitoring. This includes instruments and consumables.
- Genomics Solutions: Provides tools and services for genomic research, including RNAscopeu00ae in situ hybridization (ISH) technology, gene editing tools, and DNA/RNA purification kits.
Leadership and Structure
Bio-Techne is led by a seasoned management team. The organizational structure is largely driven by its core business segments, with dedicated leadership for Protein Sciences, Genomics, and Diagnostics. Key leadership positions include CEO, CFO, and heads of various business units and R&D.
Top Products and Market Share
Key Offerings
- Recombinant Proteins and Antibodies: High-purity recombinant proteins and a vast catalog of antibodies are foundational products. These are essential for cell culture, protein analysis, and various research assays. Competitors include Thermo Fisher Scientific, Abcam, and Novus Biologicals. While specific market share for individual products is proprietary, Bio-Techne is a recognized leader in this space.
- Immunoassays (ELISAs): ELISA kits are widely used for quantifying protein levels in biological samples. Bio-Techne offers a comprehensive range of these kits. Competitors include R&D Systems (a Bio-Techne brand), Thermo Fisher Scientific, and MilliporeSigma. Market share is fragmented but Bio-Techne is a significant player.
- RNAscopeu00ae In Situ Hybridization (ISH): This proprietary technology allows for the visualization of RNA molecules within intact cells and tissues, providing spatial gene expression information. It is a key offering from the Advanced Diagnostics segment. Competitors include ACD (part of Bio-Techne), and other FISH/ISH providers. This technology has gained significant traction and is a strong differentiator.
Market Dynamics
Industry Overview
The life sciences and diagnostics market is characterized by rapid innovation, driven by advances in genomics, proteomics, cell biology, and the increasing demand for personalized medicine and early disease detection. The market is highly competitive and fragmented, with a mix of large diversified players and specialized niche companies.
Positioning
Bio-Techne is well-positioned as a leading provider of high-quality reagents, instruments, and diagnostic solutions. Its strength lies in its comprehensive product portfolio, strong brand recognition for quality, and its expanding capabilities in advanced diagnostics and genomics, particularly through its RNAscopeu00ae technology. Its strategy of both organic growth and strategic acquisitions has allowed it to capture significant market share in its key segments.
Total Addressable Market (TAM)
The global life sciences research tools market is estimated to be tens of billions of dollars, with the diagnostics market even larger. Bio-Techne's TAM is substantial, covering areas like protein research, genomics, cell therapy development, and clinical diagnostics. The company is positioned to capture a significant portion of this TAM through its diversified offerings and its focus on high-growth areas.
Upturn SWOT Analysis
Strengths
- Strong brand reputation for high-quality research reagents.
- Diverse and comprehensive product portfolio across multiple life science disciplines.
- Proprietary technologies like RNAscopeu00ae provide a competitive edge.
- Established distribution channels and global presence.
- History of successful strategic acquisitions.
Weaknesses
- Reliance on a few key product lines for significant revenue.
- Integration challenges with acquired companies.
- Competition from larger, more diversified players with greater R&D budgets.
Opportunities
- Growing demand for personalized medicine and companion diagnostics.
- Expansion into emerging markets and developing economies.
- Leveraging AI and machine learning in drug discovery and diagnostics.
- Further development and commercialization of advanced diagnostic platforms.
- Growth in cell and gene therapy markets.
Threats
- Intensifying competition and price pressures.
- Regulatory hurdles and changes in healthcare policy.
- Economic downturns impacting research budgets.
- Rapid technological advancements by competitors.
- Supply chain disruptions and geopolitical risks.
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Agilent Technologies (A)
- Illumina, Inc. (ILMN)
- Qiagen N.V. (QGEN)
Competitive Landscape
Bio-Techne competes by offering specialized, high-quality reagents and unique technologies like RNAscopeu00ae. Its strengths lie in its deep expertise in protein sciences and its growing capabilities in advanced diagnostics. However, it faces challenges from larger competitors with broader product portfolios and greater economies of scale. Bio-Techne's ability to innovate and execute strategic acquisitions is crucial for maintaining its competitive edge.
Major Acquisitions
Exosome Diagnostics
- Year: 2020
- Acquisition Price (USD millions): 257
- Strategic Rationale: To strengthen its presence in the diagnostics market, particularly in liquid biopsy and advanced disease detection through exosome-based technologies.
Novus Biologicals
- Year: 2014
- Acquisition Price (USD millions):
- Strategic Rationale: To significantly expand its antibody portfolio and strengthen its position in the protein research market.
ACD (Advanced Cell Diagnostics)
- Year: 2019
- Acquisition Price (USD millions): 750
- Strategic Rationale: To acquire the innovative RNAscopeu00ae ISH technology, a key differentiator in spatial genomics and a significant driver of growth.
Growth Trajectory and Initiatives
Historical Growth: Bio-Techne has exhibited strong historical growth, consistently expanding its revenue base through both organic innovation and targeted acquisitions. The company has successfully integrated multiple acquisitions, diversifying its product offerings and market penetration.
Future Projections: Analyst projections generally indicate continued strong growth for Bio-Techne, driven by its expanding portfolio in diagnostics, genomics, and its established position in protein sciences. Growth is expected to be fueled by increasing demand for precision medicine, advanced diagnostics, and novel research tools. Consensus estimates for future EPS growth are typically positive.
Recent Initiatives: Recent initiatives include the continued expansion of its diagnostics portfolio, investments in its RNAscopeu00ae technology platform, and strategic partnerships aimed at accelerating the adoption of its products in clinical settings. Ongoing focus on operational efficiency and integration of recent acquisitions remains key.
Summary
Bio-Techne Corp. is a robust life sciences and diagnostics company with a strong foundation in protein sciences and a rapidly growing presence in genomics and advanced diagnostics, notably through its RNAscopeu00ae technology. Its diversified product portfolio, commitment to quality, and successful acquisition strategy have driven consistent growth. While facing competition from larger players, its innovative offerings and focus on high-demand areas like personalized medicine position it well for continued success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Bio-Techne Corp. Investor Relations website
- SEC Filings (10-K, 10-Q)
- Industry research reports from reputable financial institutions
- Financial news outlets (e.g., Bloomberg, Reuters)
Disclaimers:
This JSON output is an AI-generated analysis based on publicly available information. It is intended for informational purposes only and does not constitute financial advice. Numerical data, especially market share and acquisition prices, may be approximate or based on specific reporting periods. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Techne Corp
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 1989-02-09 | CEO, President & Director Mr. Kim Kelderman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3100 | Website https://www.bio-techne.com |
Full time employees 3100 | Website https://www.bio-techne.com | ||
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.